KIT mutations, like BRAF mutations, have the potential to change over the course of disease progression. Compared with patients without these mutations, patients with metastatic melanoma and activating mutations in KIT are more likely to respond to tyrosine kinase inhibitor imatinib. However, NCCN guidelines specify that imatinib is not a preferred agent but may be useful for those who are ineligible or unresponsive to other more effective therapeutic options. Current data suggest that at this time, c-Kit mutant patients should be treated with ICIs at first line, and only after the failure of these regimens, c-Kit inhibitors should be considered.
Learn more about the treatment of advanced-stage melanoma with KIT mutations.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston W. Tan. Fast Five Quiz: Metastatic Melanoma Treatment - Medscape - May 24, 2023.
Comments